Editorial Policies

Focus and Scope

Majalah Farmaseutic accepts submission concerning in particular fields such as pharmaceutics, pharmaceutical biology, pharmaceutical chemistry, pharmacology, and social pharmacy.

 

Section Policies

Articles

Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Peer Review Process

The primary review system in Majalah Farmaseutik is single-blind peer review. Reviewers know the author's identity, but the authors are not aware of the reviewers' identities. Manuscripts submitted to Majalah Farmaseutik will undergo significant process in order to ensure that it carries novelty and quality that appeal to the journal’s readership. There are at least five stages of review process that Majalah Farmaseutik implements:

• Initial Screening. Our Editorial Board members will asses the newly submitted manuscript for its conformity with the requirement, the manuscript’s feasibility with our Focus and Scope, as well as the quality of the content in general. A manuscript that does not pass the initial screening will be declined and returned to the Author promptly.

• Peer-review. A manuscript that passes the initial screening process will be eligible to be sent to our Reviewers. In this stage, our Editorial Assistant will ensure all the individual or private information about the Authors, including Authors’ affiliation and Acknowledgement section, are removed from the submitted file. A single manuscript will be reviewed by two reviewers. The Editorial Assistant will be responsible in combining the two review reports. The Editorial Board members will make a decision in case the two reports contradict each other. However, it is also possible to have only one Reviewer return the report to the Editorial Board. The average review process of each article may take nine to twelve months.

• First decision. A decision letter will be sent to the Author based on the reports from the Reviewers and the recommendation from the Editorial Board members. The decision can be: Declined (rejected), Revision Required (either major or minor), Accept Submission as is, or Resubmit for Review.

• Revision Stage.

  • Authors receiving the Revision Required decision are requested to revise their manuscript as recommended by our Reviewers within fourteen days. Authors will also be required to upload the Statement of Originality, their responses to article reviews, proof of plagiarism testing, and evidence of grammar checks. A revised manuscript will still be assessed for its adequacy, as well as whether it has sufficiently corresponded with the Reviewers’ suggestion, before it is given the final decision by the Editor in Chief. We kindly request that you refrain from requesting a Letter of Acceptance at this time, as our standard procedure involves thorough proofreading before final acceptance for publication.
  • Authors receiving the Resubmit for Review decision are requested to revise their manuscript in accordance with the recommendations provided by our Reviewers within fourteen days. The revised manuscript will then undergo another round of peer-review, restarting from the second stage of our peer-review process. This may extend the overall processing time.

• Completion Check and Copy Editing. The content will be carefully checked to confirm that all comments and suggestions from the editors and reviewers have been fully addressed and properly integrated into the manuscript. The revised manuscript will also be checked for consistency in style, formatting, and adherence to journal guidelines.

• Final decision. The final decision of the manuscript is either accepted or declined. At this stage, a revised manuscript that is deemed inadequate or has not seemed to have significant improvement will be declined. A manuscript that is accepted and considered to be published in Majalah Farmaseutik will receive electronic Letter of Conditional Acceptance via e-mail for Article Publication Charge (APC). Manuscripts that have fulfilled all conditions for publication in Majalah Farmaseutik will receive Letter of Acceptance. Please be informed that the Letter of Acceptance in PDF format is issued upon request.

 

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

 

Archiving

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration. More...

 

Publication Ethics

Publication Ethics and Malpractice Statement
Majalah Farmaseutik is an international peer-reviewed journal. This statement clarifies ethical conduct to all parties involved in manuscript publication Majalah Farmaseutik, including the author(s), Editor in Chief, the Editorial Board, the peer-reviewer, and the publisher (Faculty of Pharmacy, Gadjah Mada University). This statement is relied on Practice Guidelines for publication as in Committee on Publication Ethics (COPE’s Best).

Duties of Authors

  1. Reporting Standars: 
    Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behaviour and are unacceptable.
  2. Data Access and Retention: 
    Authors are asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.
  3. Originality and Plagiaris: The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others that this has been appropriately cited or quoted.
  4. Multiple, Redundant or Concurrent Publication: 
    An author should not in general publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and is unacceptable.
  5. Acknowledgement of Sources: 
    Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work.
  6. Authorship of the Paper: 
    Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.
  7. Disclosure and Conflicts of Interest: 
    All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.
  8. Fundamental errors in published works: 
    When an author discovers a significant error or inaccuracy in his/her own published work, it is the author’s obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.
  9. Hazards and Human or Animal Subjects: 
    If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.

Duties of Editors

  1. Fair Play: 
    An editor at any time evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.
  2. Confidentiality: 
    The editor and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
  3. Disclosure and Conflicts of Interest: 
    Unpublished materials disclosed in a submitted manuscript must not be used in an editor's own research without the express written consent of the author.
  4. Publication Decisions: 
    The editor board journal are responsible for deciding which of the articles submitted to the journal should be published. The validation of the work in question and its importance to researchers and readers must always drive such decisions. The editors may be guided by the policies of the journal's editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editors may confer with other editors or reviewers in making this decision.
  5. Review of Manuscripts: 
    Editor must ensure that each manuscript is initially evaluated by the editor for originality. The editor should organize and use peer review fairly and wisely. Editors should explain their peer review processes in the information for authors and also indicate which parts of the journal are peer reviewed. Editor should use appropriate peer reviewers for papers that are considered for publication by selecting people with sufficient expertise and avoiding those with conflicts of interest.

Duties of Reviewers

  1. Contribution to Editorial Decisions:
    Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper.
  2. Promptness: 
    Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process
  3. Standards of Objectivity: 
    Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.
  4. Confidentiality: 
    Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorized by the editor.
  5. Disclosure and Conflict of Interest: 
    Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
  6. Acknowledgement of Sources: 
    Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor's attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.

 

Screening for Plagiarism

Manuscripts submitted to Majalah Farmaseutik (Pharmaceutics Journal) are to be screened for plagiarism using Turnitin. Majalah Farmaseutik (Pharmaceutics Journal) will promptly reject manuscripts that are leading to either self-plagiarism or plagiarism. Authors indicated performing plagiarism or self-plagiarism will be blacklisted and disallowed to submit their manuscripts to Majalah Farmaseutik (Pharmaceutics Journal). Please refer to our Author Guideline and Publication Ethics regarding our provisions of submission.

 

Author Fees

This journal charges the following author fees.

Article Submission: 0.00 (IDR)
Authors are required to pay an Article Submission Fee as part of the submission process to contribute to review costs.

Article Processing Charge: 300K (IDR)
Authors are required to pay a fee for the Article Processing Charge (APC), after the review is complete and before receiving a letter of acceptance.

Article Publication: 0.00 (IDR)
If this paper is accepted for publication, you will be asked to pay an Article Publication Fee to cover publications costs.

If you do not have funds to pay such fees, you will have an opportunity to waive each fee. We do not want fees to prevent the publication of worthy work.